Fig. 1From: Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trialCost-effectiveness plane showing parameter uncertainty in costs and QALYs from the Markov model via 10,000 Monte Carlo simulations of the input configurations. X-axis and Y-axis were showing both difference in QALYs and costs, respectively, between infliximab and ciclosporinBack to article page